Rapamycin vs Methotrexate in Diffuse SSc

Completed · Phase 1/Phase 2

Conditions studied: Systemic Sclerosis

In brief

This is a study to determine the safety of the immunosuppressive rapamycin in patients with systemic sclerosis with diffuse cutaneous scleroderma. The effects (both good and bad) are being compared to another group of systemic sclerosis patients receiving methotrexate

Key facts

Study ID

NCT00241189

Run by

University of California, Los Angeles

People needed

17

Starts

2002-08-01

Expected to finish

2006-06-01

Last updated by the study team

2016-04-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Satisfy American College of Rheumatology classification criteria for systemic sclerosis
• Have skin thickening proximal to the elbows and/or knees (diffuse scleroderma)
• Cutaneous involvement for less than 5 years from the onset of the first non-Raynaud's manifestation

You may not qualify if…

• Severe intractable malabsorption
• Chronic debilitation from any underlying disease
• Off putative disease modifying therapies for one month prior to entry

Where it is running

• Philip Clements, MD — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.